


Please type a plus sign (+) inside this box ☐



PTO SB 813 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09 724,380
				Filing Date	Nov. 28, 2000
				First Named Inventor	MILES, Vincent J.
				Group Art Unit	1636
				Examiner Name	GUZO, D.
Sheet	2	of	10	Attorney Docket Number	A-70298-3 RMS AXG

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published.	T ²
iz	C1	Agris et al., Biochem. 25:6268-6275 (1986).	
	C2	Babiss et al., Mol. Cell. Biol. 5:2552-2558 (1985).	
	C3	Bae et al., Virology 170:282-287 (1989).	
	C4	Baroudy et al., Proc. Natl. Acad. Sci. USA 82:2143-2147 (1985).	
	C5	Beattie et al., Virology 183:419-422 (1991).	
	C6	Beck et al., Nucleic Acids Res. 11:7873-7885 (1983).	
	C7	Biegelke & Geballe Virology 177:657-667 (1990).	
	C8	Black et al., J. Virology 67:791-800 (1993).	
	C9	Boothroyd et al., Nature 290:800-802 (1981).	
	C10	Boothroyd et al., Gene 17:153-161 (1982).	
	C11	Borman et al., J. Gen. Virol. 74:1775 (1993).	
	C12	Borman and Jackson, Virology 188:685 (1992).	
	C13	Poroyagin et al., "A Factor that Specifically Binds to the 5'-Untranslated Region of Encephalomyocarditis Virus RNA," FEBS Lett. 261:237-240 (1990).	
	C14	Poroyagin et al., "RNA-Protein Interactions With the Internal translation Initiation Region of the Encephalomyocarditis Virus RNA," Nucl. Acids Res. 19:4999-5005 (1991).	
	C15	Bouloy et al., Proc. Natl. Acad. Sci. USA 75:4886-4890 (1978).	
	C16	Brown et al., J. Virol. 65:5828-5838 (1991).	
✓	C17	Brown-Driver, V. et al., "Inhibition of translation of hepatitis C virus RNA by 2'-modified antisense oligonucleotides," Antisense Nucleic Acid Drug Dev. 1999 Apr;9(2):145-54.	
✓	C18	Callahan P et al. Proc. Natl. Acad. Sci. USA 82:7337-7341 (1985).	
✓	C19	Campbell et al., J. Mol. Biol. 180:1-19 (1984).	

Examiner Signature	<i>[Signature]</i>	Date Considered	6/20/01
---------------------------	--------------------	------------------------	---------


*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

Please type a plus sign (+) inside this box ☐



PTO SB 8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	10	Application Number	09 724,380
-------	---	----	----	--------------------	------------

Complete if Known	
Filing Date	Nov. 28, 2000
First Named Inventor	MILES, Vincent J.
Group Art Unit	1636
Examiner Name	GUZO, D.
Attorney Docket Number	A-70298-3 RMS AXG

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published.	T
2	C20	Carroll & Clarke Nucleic Acids Res. 12:2461 (1984).	
	C21	Centrella and Lucas-Lenard, J. Virology 41:781-791 (1982).	
	C22	Chang et al., J. Gen. Virol. 70:3269-3280 (1989).	
	C23	Chang et al., Proc. Natl. Acad. Sci. USA 87:5158-5162 (1990).	
	C24	Chien et al., Proc. Natl. Acad. Sci. USA 88:9578-9582 (1991).	
	C25	Choo et al., Proc. Natl. Acad. Sci. USA 88:2451-2455 (1991).	
	C26	Christianson et al., Genetics 110:119-122 (1992).	
	C27	Clarke et al., Eur. J. Biochem. 193:635-641 (1990).	
	C28	Clarke et al., Nucl. Acids Res. 19:243-248 (1991).	
	C29	Cohen et al., J. Virol. 61:50-59 (1987).	
	C30	Cohen et al., Proc. Natl. Acad. Sci. USA 84:2497-2501 (1987).	
	C31	Cullen, Cell 46:973 (1986).	
	C32	Del Angel et al., Proc. Natl. Acad. Sci. USA 86:8299-8303 (1989).	
	C33	Deuchler et al., Proc. Natl. Acad. Sci. USA 84:2605-2609 (1987).	
	C34	Dinman and Wickner, "Ribosomal Frameshifting Efficiency and gag gag-pol Ratio Are Critical for Yeast MS2 Double Stranded RNA Virus Propagation," J. Virol. 66:3699 (1992).	
	C35	Dolph et al., J. Virology 62:2059-2066 (1988).	
	C36	Drug and Market Development, vol. 3, No. 9, pp. 174-180 (Feb. 15, 1993).	
	C37	Duke et al., "Sequence and Structural Elements That Contribute to Efficient Encephalomyocarditis Virus RNA Translation," Journal of Virology 66:1602-1609 (1992).	

Examiner Signature	Date Considered
--------------------	-----------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FILES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

Please type a plus sign (+) inside this box ☐



PTO SB 8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	09 724,380
				Filing Date	Nov. 28, 2000
				First Named Inventor	MILES, Vincent J.
				Group Art Unit	1636
				Examiner Name	GUZO, D
Sheet	4	of	10	Attorney Docket Number	A-70298-3 RMS AXG

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
g	C38	Earle et al., J. Gen. Virol. 69:253-263 (1988).		
	C39	Edery et al., Cell 56:303-312 (1989).		
	C40	Etchison et al., J. Biol. Chem. 257:14806-14810 (1982).		
	C41	Fields and Song, Nature, 340:245-246 (1989).		
	C42	Fiers et al., J. Supramol Struct Cell Biochem 5:357 (1981).		
	C43	Forss et al., Nucleic Acids Res. 12:6587 (1984).		
	C44	Gambani et al., Int J J. Pharm. 72:251-258 (1991).		
	C45	Galderisi et al., Expert Opinion on Emerging Drugs 6(1):69-79 (2001) ABSTRACT		
	C46	Galibert et al., Nature 281:646-650 (1979).		
	C47	Garlinkel and Katze, J. Biol. Chem. 267:9383-9390 (1992).		
	C48	Geary RS, Yu RZ, Levin AA. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2001 Apr;2(4):562-73 (ABSTRACT)		
	C49	Geballe and Mocarski, J. Virology 62:3334-3340 (1988).		
	C50	Grinell and Wagner, J. Virology 48:88-101 (1983).		
	C51	Gunnery et al., "Tat-Responsive Region RNA of Human Immunodeficiency Virus 1 Can Prevent Activation of the Double-Stranded-RNA-Activated Protein Kinase," Proc. Natl. Acad. Sci. USA 87:8687-8691 (1990)		
	C52	Gura, Science, vol. 270, pp. 575-577, Oct. 27, 1995		
	C53	Gutierrez et al., "Transient Inhibition of Foot-and-Mouth Disease Virus Infection of BHK-21 Cells by Antisense Oligonucleotides Directed Against the Second Functional Initiator AUG," Antiviral Research 22:1-13 (1993).		
	C54	Halbert et al., J. Virology 86:250-257 (1985)		
	C55	Han et al., Proc. Natl. Acad. Sci. USA 88:1711-1715 (1991)		
	C56	Hanecek R et al., J. Virol. 70(8):5203-12 (Aug 1996)		


Examiner Signature	<i>Samuel J. Guzo</i>	Date Considered	5/20/02
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number, * Applicant is to place a check mark here if English Language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐



PTO SB 8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09 724 380
				Filing Date	Nov. 28, 2000
				First Named Inventor	MILES, Vincent J.
				Group Art Unit	1636
				Examiner Name	GUZO, D.
Sheet	5	of	10	Attorney Docket Number	A-70298-3 RMS AXG

TECH CENTER 1600 2600

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2	C57	Herman, "Alternatives for the Initiation of Translation," THBS 14:219-222 (1989)	
	C58	Hershey, "Translational Control in Mammalian Cells," Ann. Rev. Biochem. 60:717-755 (1991).	
	C59	Hershey, "Introduction to Translational Initiation Factors and Their Regulation by Phosphorylation," Seminars in Virology 4:201-207 (1993).	
	C60	Huang and Schneider, Cell 65:271-280 (1991).	
	C61	Hughes et al., J. Gen. Virol. 69:49-58 (1988).	
	C62	Hughes et al., J. Gen. Virol. 67:2093-2102 (1986).	
	C63	Hughes et al., J. Gen. Virol. 70:2943-2952 (1989).	
	C64	Ilzuka et al., Virology 156:64.	
	C65	Imani and Jacobs, Proc. Natl. Acad. Sci. USA 85:7887-7891 (1988).	
	C66	Inchauspe et al., Proc. Natl. Acad. Sci. USA 88:10293 (1991).	
	C67	Inglis, Mol. Cell. Biol. 2:1644-1648 (1982).	
	C68	Jacks et al., "Characterization of Ribosomal Frameshifting in HIV-1 gag-pol expression," Nature 331:280 (1988).	
	C69	Jackson, "Initiation Without an End," Nature 353:14-15 (1991).	
	C70	Jackson et al., "The Novel Mechanism of Initiation of Picornavirus RNA Translation," Trends Biochem. Sci. 15:477-482 (1990).	
	C71	Jang et al., Enzyme 44:292-309 (1990).	
	C72	Jang and Wimmer, Genes Dev. 4:1560-1572 (1990).	
✓	C73	Jang et al., J. Virol. 63:1651 (1989).	
	C74	Jean-Jean et al., J. Virology 63:5451-5454 (1989).	


Examiner Signature	<i>[Signature]</i>	Date Considered	6/20/00
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box ☐



PTO SB 8B (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/A/TO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09 724,380		
		Filing Date	Nov. 28, 2000		
		First Named Inventor	MILLES, Vincent J.		
		Group Art Unit	1636		
		Examiner Name	GUZO, D.		
Sheet	6	of	10	Attorney Docket Number	A-70298-3 RMS AXG

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published.	
12	C75	Jenkins, J. Gen. Virol 68:1835-1848 (1987).	
	C76	Kato et al., Proc. Natl. Acad. Sci. USA 87:9524-9528 (1990).	
	C77	Katze, J. Interferon Res. 12:241-248 (1992).	
	C78	Katze, "Games Viruses Play: a Strategic Initiative Against the Interferon-Induced dsRNA Activated 68,000 M.sub.r Protein Kinase," Seminars in Virology 4:259-268 (1993).	
	C79	Katze et al., J. Virology 62:3710-3717 (1988).	
	C80	Kozak, "The Scanning Model for Translation: An Update," J. Cell. Biol. 108:229-241 (1989).	
	C81	Kozak, "A Consideration of Alternative Models for the Initiation of Translation in Eukaryotes," Crit. Rev. Biochem. Mol. Biol. 27:385-402 (1992).	
	C82	Kuhn et al., J. Virol. 64:4625 (1990).	
	C83	Kwong et al., J. Virology 62:912-921 (1988).	
	C84	La Monica et al., J. Virology 57:515 (1986).	
	C85	Lee and Zuker, J. Mol. Biol. 216:729-741 (1990).	
	C86	Lee et al., Proc. Natl. Acad. Sci. USA 87:6208-6212 (1990).	
	C87	Lima et al., J. Biol. Chem. 272(1):626-638 (1997)	
	C88	Lindberg et al., Virology 156:50 (1987).	
	C89	Linemeyer et al., J. Virol. 54:252 (1985).	
	C90	Luz and Beck, J. Virol. 65:6486-6494 (1991).	
	C91	Ma and Mathews, "Computative Analysis of the Structure and Function of Adenovirus Virus Associated RNAs," J. Virol. 67:6605-6617 (1993)	
	C92	Maccjak and Sarnow, "Internal Initiation of Translation Mediated by the 5' Leader of a Cellular mRNA," Nature 353:90-94 (1991)	

Examiner Signature	<i>[Signature]</i>	Date Considered	11/28/00
--------------------	--------------------	-----------------	----------


*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPFP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FITS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

Please type a plus sign (+) inside this box ☐



PTO SB 8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to furnish information to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09 724,380
				Filing Date	Nov. 28, 2000
				First Named Inventor	MILES, Vincent J.
				Group Art Unit	1636
				Examiner Name	GUZO, D.
Sheet	7	of	10	Attorney Docket Number	A-70298-3 RMS AXG

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published	T ²	
2	C93	Mathews, "Viral Evasion of Cellular Defense Mechanisms: Regulation of the Protein Kinase DAI by RNA Effectors," Seminars in Virology 4:247-257 (1993).		
	C94	Mathews and Shenk, "Adenovirus Virus-Associated RNA and Translation Control," J. Virology 65:5657-5662 (1991).		
	C95	Meerovitch and Sonenberg, Seminars Virol. 4:217 (1993).		
	C96	Meerovitch et al., J. Virol. 67:3798 (1993).		
	C97	Meerovitch et al., "A Cellular Protein That Binds to the 5'-Noncoding Region of Poliovirus RNA: Implications for Internal Translation Initiation," Gene Dev. 3:1026-1034 (1989).		
	C98	Mellits & Mathews, "Effects of Mutations in Stem and Loop Regions on the Structure and Function of Adenovirus VA RNA, subunit 1," EMBO J. 7:2849-2859 (1988).		
	C99	Mellits, et al., "Role of the Apical Stem in Maintaining the Structure and Function of Adenovirus Virus-Associated RNA," J. Virol. 66:2369-2377 (1992).		
	C100	Miller and Hinnebusch, Genes Dev. 3:1217 (1989).		
	C101	Miroshnichenko, et al., "Inhibition of Adenovirus 5 Replication in COS-1 Cells by Antisense RNAs Against the Viral E1A Region," Gene 84:83-89 (1989).		
	C102	Mizutani et al., J. Virol. vol. 56, No. 2, pp. 628-632, Nov. 1985.		
	C103	Molla et al., "Cardioviral Internal Ribosomal Entry Site is Functional in a Genetically Engineered Dicistronic Poliovirus," Nature 356:255-257 (1992).		
	C104	Moreland et al., J. Virol. 65:1168-1176 (1991).		
	C105	Najarian et al., Proc. Natl. Acad. Sci. USA 82:2627 (1985).		
	C106	Najita and Sarnow, Proc. Natl. Acad. Sci. USA 87:5846-5850 (1990).		
	C107	Nicholson et al., J. Virol. 65:5886 (1991).		
	C108	Tomoto A, Omata T, Toyoda H, Kuge S, Hone H, Kataoka Y, Genba Y, Nakano Y, Imura N. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci USA. 1982 Oct;79(19):5793-7.		
	C109	Ohara et al., Virology 164:245 (1988).		
2	C110	Okamoto et al., "Full length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes," Virology 1992 May;188(1):331-41		

Examiner Signature	Date Considered
--------------------	-----------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPFP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND THIS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

RECEIVED

Please type a plus sign (+) inside this box ➡ ☐



PTO SB 8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09 724,380		
		Filing Date	Nov. 28, 2000		
		First Named Inventor	MILLES, Vincent J.		
		Group Art Unit	1636		
		Examiner Name	GUZO, D.		
Sheet	8	of	10	Attorney Docket Number	A-70298-3 RMS AXG

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published.	T ²
2	C111	Okamoto et al., J. Gen. Virol 72:2697-2704 (1991).	
	C112	Palmenberg et al., Nucl. Acids Res. 12:2969-29851 (1984).	
	C113	Paul et al., Virus Res. 8:153-171 (1987).	
	C114	Peaver et al., Virology 165:1 (1988).	
	C115	Peaver et al., J. Virol. 61:1507 (1987).	
	C116	Pelletier and Sonenberg, J. Virol. 63:441 (1989).	
	C117	Pelletier et al., Mol. Cell. Biol. 8:1103-1112 (1988).	
	C118	Pelletier et al., J. Virol 62:4486 (1988).	
	C119	Pestova et al., "Translation of Poliovirus RNA: Role of an Essential cis-Acting Oligopyrimidine Element Within the 5' Nontranslated Region and Involvement of a Cellular 57-Kilodalton Protein," J. Virol 65:6194-6204 (1991).	
	C120	Pestova et al., "Distinct Models of Poliovirus Polypeptide Initiation in Vitro," Virus Research 14:107-118 (1989).	
	C121	Pilder et al., Mol. Cell. Biol. 6:470-476 (1986).	
	C122	Pilipenko et al., "Procarvotic-like cis Elements in the Cap-Independent Internal Translation on Picornavirus RNA," Cell 68:119-131 (1992).	
	C123	Pilipenko et al., Virology 168:201 (1989).	
	C124	Plotch et al., Cell 23:847-858 (1981).	
	C125	Pollard et al., J. Virol. 63:4949-4951 (1989).	
	C126	Qian et al., Mol. Cell. Biol. 11:5312-5320 (1991).	
	C127	Racaniello & Baltimore Proc. Natl. Acad. Sci. USA 78:4887-4891 (1981).	

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>[Date]</i>
---------------------------	--------------------	------------------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

8-504 (SEPTEMBER 1997)

RECEIVED

Please type a plus sign (+) inside this box ☐



PTO SB 8B (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09 724,380
				Filing Date	Nov. 28, 2000
				First Named Inventor	MILLES, Vincent J.
				Group Art Unit	1636
				Examiner Name	GUZO, D.
Sheet	9	of	10	Attorney Docket Number	A-70298-3 RMS AXG

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published.	T ²
2	C128	Remington's Pharmaceutical Sciences, Mack Publishing Co., A.R. Gennaro ed. (1985).	
	C129	Rice and Roberts, J. Virology 47:529-539 (1983).	
	C130	Robertson et al., J. Virol. 54:651 (1985).	
	C131	Roy et al., J. Virology 65:632-640 (1991).	
	C132	Ryan et al., J. Gen. Virol. 71:2291-2299 (1990).	
	C133	Samuel, "The eIF-2.alpha. Protein Kinases, Regulators of Translation in Eukaryotes from Yeasts to Humans," J. Bio. Chem. 268:7603-7606 (1993).	
	C134	Scheper et al., "The 5' Untranslated Region of Encephalomyocarditis Virus Contains a Sequence For Very Efficient Binding of Eukaryotic Initiation Factor eIF-2 B3," Biochem. Biophys. Acta 1089:220-226 (1991).	
	C135	Schleiss et al., J. Virology 65:6782-6789 (1991).	
	C136	Sen and Lengyel, "The Interferon System," J. Bio. Chem 267:5017-5020 (1992).	
	C137	Shih et al., "Effects of cDNA Hybridization on Translation of Encephalomyocarditis Virus RNA," J. Virol. 61:2033-2037 (1987).	
	C138	Sikorski & Heiter, Genetics 122:19-27 (1989).	
	C139	Skern et al., Nucleic Acids Res. 13:2111 (1985).	
	C140	Sonenburg, "Measures and Countermeasures In the Modulation of Initiation Factor Activities By Viruses," The New Biologist 2:402-409 (1990).	
	C141	Sonenberg and Meerovitch, "Translation of Poliovirus mRNA," Enzyme 44:278-291 (1990).	
	C142	Stanners et al., Cell 11:273-281 (1977).	
	C143	Stanway G et al., Proc. Natl. Acad. Sci. USA 81:1539-1543 (1984).	
	C144	Stanway et al., Nucl. Acids Res. 12:7859-7875 (1984).	
	C145	Takamizawa et al., J. Virology 65:1105-1113 (1991).	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐



PTO SB 8B (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09 724,380
				Filing Date	Nov. 28, 2000
				First Named Inventor	MILES, Vincent J.
				Group Art Unit	1636
				Examiner Name	GUZO, D.
Sheet	10	of	10	Attorney Docket Number	A-70298-3 RMS AXG

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published.		T ²
<i>g</i>	C146	Thomas and Wagner, Biochemistry 22:1540-1546 (1983).		
	C147	Thompson et al., Clin. Chem. 35:1878-1881 (1989).		
	C148	Toyoda et al., J. Mol. Biol. 174:561-585 (1984).		
	C149	Tracy et al., Virus Res. 3:263-270 (1985).		
	C150	Trono et al., Science 241:445-448.		
	C151	Tsukivama-Kohara et al., J. Virol. 66:1476 (1992).		
	C152	Villanueva et al., Gene 23:185-194 (1983).		
	C153	Watson et al., Virology 185:206-216 (1991).		
	C154	Weddell et al., Proc. Natl. Acad. Sci. USA 82:2618-2622 (1985).		
	C155	Wilson et al., "HIV Expression Strategies: Ribosomal Frameshifting Is Directed by a Short Sequence in Both Mammalian and Yeast Systems," Cell 55:1559 (1988).		
	C156	Witherell et al., Biochemistry 32:8268 (1993).		
<i>u</i>	C157	Yoo et al., "5' End-Dependent Translation Initiation of Hepatitis C Viral RNA and the Presence of Putative Positive and Negative Translational Control Elements Within the 5' Untranslated Region," Virology 191:889-899 (1992).		
<i>z</i>	C158	ZHANG et al., Antimicrob Agents Chemother 43(2):347-53 (Feb 1999).		

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>11/28/00</i>
--------------------	--------------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FILLS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.